The estimated Net Worth of Peggy Scherle is at least $1.68 Milhão dollars as of 26 August 2021. Dr Scherle owns over 7,714 units of Prelude Therapeutics Inc stock worth over $894,670 and over the last 4 years he sold PRLD stock worth over $781,709.
Dr has made over 6 trades of the Prelude Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 7,714 units of PRLD stock worth $11,031 on 26 August 2021.
The largest trade he's ever made was exercising 20,000 units of Prelude Therapeutics Inc stock on 27 July 2021 worth over $28,600. On average, Dr trades about 6,000 units every 14 days since 2021. As of 26 August 2021 he still owns at least 178,934 units of Prelude Therapeutics Inc stock.
You can see the complete history of Dr Scherle stock trades at the bottom of the page.
Dr. Peggy A. Scherle Ph.D. is the Chief Scientific Officer at Prelude Therapeutics Inc.
Dr D is 60, he's been the Chief Scientific Officer of Prelude Therapeutics Inc since . There are 1 older and 3 younger executives at Prelude Therapeutics Inc. The oldest executive at Prelude Therapeutics Inc is Dr. Deborah Morosini, 62, who is the Exec. VP & Chief of Clinical Affairs.
Peggy's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805.
Over the last 5 years, insiders at Prelude Therapeutics Inc have traded over $822,895 worth of Prelude Therapeutics Inc stock and bought 5,875,215 units worth $87,687,261 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., David P Bonita, eAdvisors Llc Orbi Med Capit.... On average, Prelude Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $608,735. The most recent stock trade was executed by Jane Huang on 4 July 2024, trading 9,375 units of PRLD stock currently worth $46,875.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Prelude Therapeutics Inc executives and other stock owners filed with the SEC include: